Alberta Y Hoi

List of Publications by Year in Descending Order

52 papers	1,444 citations	20 h-index	37 g-index
61 ext. papers	1,955 ext. citations	5.9 avg, IF	4.61 L-index

#	Paper	IF	Citations
52	Purtscher-like retinopathy in anti-MDA5 dermatomyositis: a window to underlying microvasculopathy. *Clinical and Experimental Rheumatology*, **2022**, 40, 473-474	2.2	
51	TNot at targetT prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.. *Arthritis Research and Therapy*, **2022**, 24, 70	5.7	1
50	Purtscher-like retinopathy in anti-MDA5 dermatomyositis: a window to underlying microvasculopathy.. *Clinical and Experimental Rheumatology*, **2022**,	2.2	
49	Cytokines: Their Role in Amplifying SLE Pathogenesis **2021**, 109-131		
48	Granulocyte colony-stimulating factor is not pathogenic in lupus nephritis. *Immunity, Inflammation and Disease*, **2021**, 9, 758-770	2.4	2
47	Treatment Update in Systemic Lupus Erythematous. *Rheumatic Disease Clinics of North America*, **2021**, 47, 513-530	2.4	2
46	Disease course following High Disease Activity Status revealed patterns in SLE. *Arthritis Research and Therapy*, **2021**, 23, 191	5.7	
45	Algorithm for calculating high disease activity in SLE. *Rheumatology*, **2021**, 60, 4291-4297	3.9	5
44	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. *Rheumatology*, **2021**, 60, 5185-5193	3.9	1
43	Global epidemiology of systemic lupus erythematosus. *Nature Reviews Rheumatology*, **2021**, 17, 515-532	8.1	29
42	High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. *Lupus Science and Medicine*, **2020**, 7,	4.6	6
41	Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. *Lupus Science and Medicine*, **2020**, 7,	4.6	7
40	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. *Lancet Rheumatology, The*, **2020**, 2, e24-e30	14.2	22
39	Associations of metabolic syndrome in SLE. *Lupus Science and Medicine*, **2020**, 7,	4.6	3
38	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. *International Journal of Rheumatic Diseases*, **2020**, 23, 1255-1257	2.3	9
37	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. *Arthritis Care and Research*, **2020**, 72, 1289-1295	4.7	12
36	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. *Lancet Rheumatology, The*, **2019**, 1, e95-e102	14.2	26

35	Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. *Clinical and Translational Immunology*, **2019**, 8, e01047	6.8	15
34	Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus. *Frontiers in Immunology*, **2019**, 10, 1649	8.4	2
33	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. *Lancet Rheumatology, The*, **2019**, 1, e103-e110	14.2	19
32	Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. *Clinical and Translational Immunology*, **2019**, 8, e01093	6.8	22
31	A potential association between IL-3 and type I and III interferons in systemic lupus erythematosus. *Clinical and Translational Immunology*, **2019**, 8, e01097	6.8	7
30	Development of the Asia Pacific Lupus Collaboration cohort. *International Journal of Rheumatic Diseases*, **2019**, 22, 425-433	2.3	14
29	Analysis of Serum Interleukin (IL)-1 and IL-18 in Systemic Lupus Erythematosus. *Frontiers in Immunology*, **2018**, 9, 1250	8.4	57
28	Discordance of patient and physician health status concerns in systemic lupus erythematosus. *Lupus*, **2018**, 27, 501-506	2.6	35
27	Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. *Lupus Science and Medicine*, **2018**, 5, e000277	4.6	8
26	Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis. *Clinical and Translational Immunology*, **2018**, 7, e1042	6.8	11
25	The Rare Anaphylaxis-Associated FcRIIa3 Exhibits Distinct Characteristics From the Canonical FcRIIa1. *Frontiers in Immunology*, **2018**, 9, 1809	8.4	7
24	Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap. *Journal of Rheumatology*, **2017**, 44, 271-278	4.1	3
23	Trimethoprim-induced aseptic meningitis: a reminder case review. *International Journal of Rheumatic Diseases*, **2017**, 20, 664-665	2.3	3
22	Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?. *Lupus Science and Medicine*, **2017**, 4, e000212	4.6	20
21	Systemic lupus erythematosus: an update. *Medical Journal of Australia*, **2017**, 206, 215-220	4	23
20	The Australian Lupus Registry and Biobank: a timely initiative. *Medical Journal of Australia*, **2017**, 206, 194-195	4	10
19	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). *Annals of the Rheumatic Diseases*, **2016**, 75, 1615-21	2.4	235
18	Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. *Scientific Reports*, **2016**, 6, 34604	4.9	53

17	Independent association of glucocorticoids with damage accrual in SLE. *Lupus Science and Medicine*, **2016**, 3, e000157	4.6	53
16	The art of managing medical uncertainty. *Lancet, The*, **2016**, 387, 1026	40	2
15	Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. *Lupus Science and Medicine*, **2015**, 2, e000105	4.6	7
14	Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. *Lupus Science and Medicine*, **2015**, 2, e000064	4.6	45
13	Asian lupus in a multi-ethnic society: what can be learnt?. *International Journal of Rheumatic Diseases*, **2015**, 18, 113-6	2.3	7
12	Brief Report: Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2015**, 67, 3219-25	9.5	78
11	The need to define treatment goals for systemic lupus erythematosus. *Nature Reviews Rheumatology*, **2014**, 10, 567-71	8.1	33
10	Is there still a role for abatacept in the treatment of lupus?. *Expert Opinion on Biological Therapy*, **2014**, 14, 1345-50	5.4	10
9	Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. *Lupus*, **2013**, 22, 1425-30	2.6	49
8	Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. *Lupus*, **2013**, 22, 873-84	2.6	62
7	Asian ethnicity in systemic lupus erythematosus: an Australian perspective. *Internal Medicine Journal*, **2013**, 43, 618-24	1.6	18
6	Clinical associations of serum interleukin-17 in systemic lupus erythematosus. *Arthritis Research and Therapy*, **2013**, 15, R97	5.7	101
5	Abatacept in the treatment of lupus. *Expert Opinion on Biological Therapy*, **2012**, 12, 1399-406	5.4	15
4	TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. *Journal of Autoimmunity*, **2010**, 35, 291-8	15.5	91
3	Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. *Inflammation and Allergy: Drug Targets*, **2007**, 6, 183-90		74
2	Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. *Journal of Immunology*, **2006**, 177, 5687-96	5.3	111
1	Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?. *Immunology and Cell Biology*, **2003**, 81, 367-73	5	17